Cargando…

Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK

AIM: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagshaw, Emma, Enoch, David A, Blackney, Michael, Posthumus, Jan, Kuessner, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190279/
https://www.ncbi.nlm.nih.gov/pubmed/29911889
http://dx.doi.org/10.2217/fmb-2018-0119
_version_ 1783363533445005312
author Bagshaw, Emma
Enoch, David A
Blackney, Michael
Posthumus, Jan
Kuessner, Daniel
author_facet Bagshaw, Emma
Enoch, David A
Blackney, Michael
Posthumus, Jan
Kuessner, Daniel
author_sort Bagshaw, Emma
collection PubMed
description AIM: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs with ISAV versus L-AMB followed by POSA. MATERIALS & METHODS: As indirect comparisons have demonstrated similar efficacy between the comparators, a cost-minimization approach was taken. Drug acquisition, administration & monitoring, and hospitalization costs were evaluated from the healthcare system perspective. RESULTS: Per-patient costs were UK£14,842 with ISAV versus UK£18,612 with L-AMB followed by POSA. Savings were driven by drug acquisition, and administration & monitoring costs. CONCLUSION: ISAV has the potential to reduce IMD treatment costs relative to L-AMB followed by POSA.
format Online
Article
Text
id pubmed-6190279
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-61902792018-10-19 Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK Bagshaw, Emma Enoch, David A Blackney, Michael Posthumus, Jan Kuessner, Daniel Future Microbiol Research Article AIM: Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs with ISAV versus L-AMB followed by POSA. MATERIALS & METHODS: As indirect comparisons have demonstrated similar efficacy between the comparators, a cost-minimization approach was taken. Drug acquisition, administration & monitoring, and hospitalization costs were evaluated from the healthcare system perspective. RESULTS: Per-patient costs were UK£14,842 with ISAV versus UK£18,612 with L-AMB followed by POSA. Savings were driven by drug acquisition, and administration & monitoring costs. CONCLUSION: ISAV has the potential to reduce IMD treatment costs relative to L-AMB followed by POSA. Future Medicine Ltd 2018-09 2018-06-18 /pmc/articles/PMC6190279/ /pubmed/29911889 http://dx.doi.org/10.2217/fmb-2018-0119 Text en © 2018 Basilea Pharmaceutica International Ltd, Basel This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research Article
Bagshaw, Emma
Enoch, David A
Blackney, Michael
Posthumus, Jan
Kuessner, Daniel
Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
title Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
title_full Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
title_fullStr Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
title_full_unstemmed Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
title_short Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
title_sort economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin b in the uk
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190279/
https://www.ncbi.nlm.nih.gov/pubmed/29911889
http://dx.doi.org/10.2217/fmb-2018-0119
work_keys_str_mv AT bagshawemma economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk
AT enochdavida economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk
AT blackneymichael economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk
AT posthumusjan economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk
AT kuessnerdaniel economicimpactoftreatinginvasivemolddiseasewithisavuconazolecomparedwithliposomalamphotericinbintheuk